Menu
← Oncology Approval Tracker
FDA DECISION ·
Ayvakit
avapritinib · Blueprint Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis, mast cell leukemia and systemic mastocytosis with an associated hematologic neoplasm.
LAMPGEN ANALYSIS
Why it matters
The decision extends KIT inhibition to three advanced mast cell neoplasm subtypes.
What research teams should watch
Capture diagnostic subtype, platelet counts and interruptions so the safety analysis reflects the treated population.
PRIMARY RECORDS